Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

By J. Baselga, S. Swain. Nature Reviews. Cancer, 2009

1,208 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/5f3a56caf207c08b43f05588f2b94d4a6f5d7334

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Ryuji Hamamoto
2. Takehiro Suzuki
3. N. Dohmae
4. Yusuke Nakamura
5. Yuichiro Yoshioka
6. Y. Matsuo
7. Toshiaki Watanabe
8. G. Tsurita

In Oncology

1. David P. Lane
2. S. Swain
3. Alan R. Fersht
4. Ryuji Hamamoto

Citations in the corpus

• Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization (2017, methodology): “HER2 is well known to play an essential role in tumorigenesis in several types of cancer through activation of its downstream signaling pathways involved in cell proliferation, differentiation, angiogenesis, and apoptosis [3].”
• Awakening guardian angels: drugging the p53 pathway (2009, background): “gov/drugdictionary/?CdrID=269659">lapatinib , which is efficacious in breast cancers with amplification of ERBB2 (Ref”
• Targeting HER2-positive breast cancer: advances and future directions (2022, background): “There is no known ligand for HER2, but it is a preferred dimerization partner for the other HER proteins, especially HER3 (ref.(14)).”